Скачать или смотреть Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL

Andrew Davies, MRCP, PhD, University of Southampton, Southampton, UK, discusses the results from a primary analysis of the Phase III TRANSFORM study (NCT03575351), which compared lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) with salvage chemotherapy followed by autologous stem cell transplantation (autoSCT) in second-line large B-cell lymphoma (LBCL). At a follow-up of 17.5 months, results demonstrated that patients receiving treatment with liso-cel had a superior progression-free and event-free survival (PFS; EFS). Liso-cel was safe, with low rates of cytokine release syndrome (CRS) and neurotoxicity observed in patients. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.